Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]-AG-120 in healthy males
NCT02489513Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML) and cholangiocarcinoma (CCA), sponsored by Agios Pharmaceuticals. Primary endpoints: Pharmacokinetics - Total [14C] Whole blood and plasma up to 29 days, Pharmacokinetics of single dose of AG-120 (Cmax) up to 29 days and 3 more. Started Jun 2015; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02489513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489513.